美托洛尔治疗慢性充血性心力衰竭的疗效与安全性观察

目的:观察美托洛尔治疗慢性充血性心力衰竭(CHF)的疗效与安全性。方法:所有入选病例均在常规治疗基础上进入试验。将68例CHF患者随机分为两组,治疗组35例,在常规治疗基础上加服美托洛尔,逐渐加至目标剂量或最大耐受量;对照组33例,维持常规治疗。治疗6个月,观察两组患者的临床资料、血压、心率,并比较两组治疗后6个月内因CHF再住院率。结果:治疗组均可耐受合适剂量的美托洛尔,治疗6个月后两组左室舒张末内径(LVEDD)、左室收缩末内径(LVESD)以及左室射血分数(LVEF)值都有明显改善(P<0.01),但治疗组明显优于对照组,差异有统计学意义(P<0.05);6个月内因CHF再入院率,治疗组为22.9%,对照组为39.4%。结论:美托洛尔治疗慢性CHF可明显改善患者的心功能,改善心肌重塑,降低患者因CHF的再入院率。

Study of metoprolol on the patients of chronic congestive heart failure

Objective:To investigate the efficacy and safety of Metoprolol on chronic congestive heart failure(CHF).Methods:On a basic medical therapy including digitalis,diuretics and ACEI,Sixty-eight chronic heart-failure patients were divided randomly into observational group and control group for a 6-month follow-up period.The changes of clinical manifestation,BP,HR in the two groups were observed after 6 month-treatment,and the readmission rate induced by CHF were compared between the two groups after 6 months later.Results:LVEDD,LVESD and LVEF in both groups were obviously improved after 6-month treatment compared with those before treatment(P<0.01),but there was significant differences between the two groups(P<0.05).The readmission rate induced by CHF was 22.9 % in Metoprolol group and 39.4 % in control group after 6-months follow-up.Conclusion:Metoprolol therapy can improve heart function markedly,reverse LV remodeling in patients with chronic CHF and low down readmission rate induced by CHF.